Humacyte, Inc.

Humacyte, Inc., indexed under SPAC ticker AHAC, is a regenerative medicine company that completed its de-SPAC transaction with Alpha Healthcare Acquisition Corp. III, sponsored by Alpha Healthcare Advisors, LLC, in 2021. Based in Durham, North Carolina, Humacyte develops bioengineered human acellular vessels designed for vascular surgical applications and operates in the healthcare biotechnology sector. The company filed an 8-K with the SEC on June 11, 2025, continuing its post-merger public reporting obligations under the Humacyte, Inc. corporate name. To access comprehensive filing histories, SPAC transaction data, and real-time analytics across the de-SPAC universe, sign up for full access at SpacDesk.